Nutrient and metabolite interventions for neurodegenerative diseases show inconsistent clinical translation
Dietary nutrients show mixed results for brain diseases in lab and early human data
This narrative review synthesizes evidence on nutrients and metabolites for Alzheimer's, Parkinson's, multiple sclerosis, and amyotrophic la…
Nutrients like vitamins and marine compounds show promise in labs, but human evidence for brain diseases remains inconsistent and unclear.
Narrative review explores ferroptosis-immune crosstalk in CNS diseases as therapeutic target
New hope for brain diseases by targeting a deadly cell death cycle
This narrative review synthesizes evidence on the interplay between ferroptosis and immune responses in CNS disorders including Alzheimer's,…
Scientists found a way to stop a deadly cell death cycle that makes brain diseases worse, offering new hope for patients with Alzheimer's an…
Earlier salivary melatonin onset associated with respiratory symptoms in early amyotrophic lateral sclerosis
Sleep Timing Could Predict Survival in Early ALS
This prospective longitudinal observational study assessed salivary dim-light melatonin onset in 50 people living with amyotrophic lateral s…
New research suggests sleep timing predicts how fast ALS gets worse and who survives longer without extra help.
Network meta-analysis compares pharmacological and biological therapies for amyotrophic lateral sclerosis
New ALS Therapy Combo Shows Promise For Slowing Functional Decline
This network meta-analysis synthesized data from 109 trials involving 16,353 participants to evaluate pharmacological and biological therapi…
A major analysis suggests combining cell therapy with neuroprotective drugs may help ALS patients maintain physical function longer, though …
Reeldesemtiv showed no impact on device use in ALS trial terminated early for futility
Wheelchair access varies wildly, and drug trial ended early without benefit for ALS patients
This Phase 3 randomized clinical trial enrolled 482 participants with amyotrophic lateral sclerosis (ALS) across 83 sites.
Access to wheelchairs differs greatly by region, and a major drug trial for ALS stopped early because it did not help patients.
Secondary analysis of pooled ALS trial data reveals entropy-based functional domain trajectories
New Method Reveals Hidden Treatment Signals in ALS Trials
This secondary analysis of pooled clinical trial data from the PRO-ACT database examined Shannon entropy trajectories of ALSFRS functional d…
This study suggests that the way we measure success in ALS clinical trials might be hiding real treatment benefits, and a new mathematical a…
Masitinib 4.5 mg/kg/day associated with survival in ALS post-hoc analysis
This Drug Could Add Nearly Two Years to ALS Life
This post-hoc analysis of a randomized, double-blind, placebo-controlled trial in 130 ALS patients found that masitinib 4.5 mg/kg/day was as…
A new look at data suggests a specific drug might significantly extend life for some people with ALS.
Meta-analysis links speech features to severity in Parkinsons, cerebral palsy, and ALS
Speech patterns may help track disease severity in Parkinsons and other conditions
This meta-analysis synthesizes evidence from 890 speakers across 5 languages to evaluate a training-free method for assessing speech degrada…
A new computer method tracks Parkinson's and other disease severity by measuring how specific speech sounds change without needing special t…
Cross-sectional CSF proteomic analysis identifies ALS-specific biomarker signature
ALS Blood Test Breakthrough Could Speed Diagnosis
This observational cross-sectional study analyzed CSF proteomics in 237 participants to identify ALS-specific biomarkers.
A new five-protein blood test pattern could finally help doctors spot ALS early, before nerve damage becomes too advanced.
Systematic review finds gut microbiome dysbiosis associated with ALS progression
Could gut bacteria changes be linked to ALS, or just happen alongside it?
This systematic review with narrative synthesis examined 61 studies on gut microbiome alterations in ALS.
People with ALS often show reduced gut bacteria diversity, but it is still unclear if these changes cause the disease or simply happen along…
Observational study finds no association between ZFHX3 GGC repeat expansions and ALS risk
New DNA Scan Rules Out ALS Link
This observational research article examined ZFHX3 GGC repeat expansions in 5,785 people with ALS and 7,982 healthy controls.
A major genetic test confirms that a specific repeat in your DNA does not cause ALS, even though it can cause a different movement disorder.
REDDI pipeline improves balanced accuracy for classifying MCI, MS, Parkinson's, and ALS using MEG data
Can a new computer tool help doctors spot brain diseases faster and more accurately?
This study developed a machine learning framework called REDDI that utilizes MEG resting-state data and Riemannian geometry for classifying…
A new computer tool helps doctors distinguish between hard-to-tell-apart brain diseases like Parkinson's and ALS with 13% better accuracy.
Questions about Amyotrophic Lateral Sclerosis
Does the way my body functions change differently in amyotrophic lateral sclerosis over time?
Yes, ALS causes progressive changes in motor, respiratory, bulbar, and cognitive functions, with functional decline measurable over time.
Full answer →How do different treatments for amyotrophic lateral sclerosis compare when looking at many trials together?
A network meta-analysis of 109 trials found that combining cell therapy with neuroprotective agents may slow ALS progression most, while exercise and respiratory interventions also show benefits.
Full answer →Can a specific protein signature in spinal fluid help identify amyotrophic lateral sclerosis?
Yes, a specific protein signature in spinal fluid can help identify ALS, with a five-protein panel showing high accuracy in distinguishing ALS from healthy controls.
Full answer →Did the drug Reeldesemtiv help people with amyotrophic lateral sclerosis use their devices better?
No, reldesemtiv did not help people with ALS use devices like wheelchairs or communication aids; a trial found no impact on device use and was stopped early for futility.
Full answer →All Amyotrophic Lateral Sclerosis Articles
- Nutrient and metabolite interventions for neurodegenerative diseases show inconsistent clinical translation
- Narrative review explores ferroptosis-immune crosstalk in CNS diseases as therapeutic target
- Earlier salivary melatonin onset associated with respiratory symptoms in early amyotrophic lateral sclerosis
- Network meta-analysis compares pharmacological and biological therapies for amyotrophic lateral sclerosis
- Reeldesemtiv showed no impact on device use in ALS trial terminated early for futility
- Secondary analysis of pooled ALS trial data reveals entropy-based functional domain trajectories
- Cross-sectional CSF proteomic analysis identifies ALS-specific biomarker signature
- Masitinib 4.5 mg/kg/day associated with survival in ALS post-hoc analysis
- Meta-analysis links speech features to severity in Parkinsons, cerebral palsy, and ALS
- Systematic review finds gut microbiome dysbiosis associated with ALS progression
- Observational study finds no association between ZFHX3 GGC repeat expansions and ALS risk
- REDDI pipeline improves balanced accuracy for classifying MCI, MS, Parkinson's, and ALS using MEG data
- Systematic review validates iPSC-derived organoids as models for ALS pathology compared to traditional 2D or animal models
- Muscle ultrasonography shows high diagnostic accuracy for fasciculation detection in ALS
- FDG-PET reveals dysregulated glucose metabolism as a common feature across late-onset neurodegenerative diseases with unique patterns
- Meta-analysis finds no significant association between statin use and ALS survival outcomes